-
Fenipentol Workflows for Secretion and Fibrosis
2026-09-22
Fenipentol is a defined small-molecule tool for connecting hepatobiliary secretion, ESR1-oriented hypotheses, and translational liver assays. This workflow explains how to prepare, dose, compare, and troubleshoot Fenipentol while clearly separating direct evidence from findings on its positional isomer.
-
Talabostat mesylate: Reliable Assay Design
2026-09-21
This scenario-based guide explains how Talabostat mesylate (SKU B3941) can support mechanistic cell viability, cytotoxicity, and tumor microenvironment studies. It connects formulation handling, keratinocyte inflammasome evidence, FAP-dependent comparisons, and practical vendor-selection criteria to improve interpretation and workflow consistency.
-
From RNA Modification Maps to Translational Strategy
2026-09-21
Spatially resolved RNA modification profiling is shifting the field from cataloging chemical marks to understanding where modified RNAs act. This article examines how APEX-RNA-MS, orthogonal validation, and carefully controlled use of IMP can help translational researchers convert cellular localization signals into testable biological and development hypotheses.
-
ERADECs for Targeted Degradation of TM Proteins
2026-09-20
Song et al. establish ERAD-engaging chimeras (ERADECs), a small-molecule platform that redirects the ER-associated degradation pathway toward transmembrane proteins. By identifying desonide as a binder of the ER E3 ligase SYVN1 and applying it to PD-L1 degradation, the study provides a mechanistic route for overcoming limitations of lysosome- and proteasome-oriented targeted protein degradation.
-
Anti-b Targets mTOR-Linked Hepatic Steatosis
2026-09-19
A 2025 British Journal of Pharmacology study shows that Anti-b reduces diet- and oleic acid-induced dyslipidaemia and hepatic lipid accumulation in rodents and liver cells. Its mechanistic contribution is the integration of mTOR binding and thermal-stability evidence with PPARγ and SREBP1 pathway analysis, providing a basis for studying mTOR-linked lipid metabolism.
-
KG-501: Mapping CREB Control in CAC Models
2026-09-19
KG-501 provides a pharmacological way to interrogate CREB–CBP coactivator control in colitis-associated cancer models. This article distinguishes direct transcriptional effects from TLR4 pathway dependence and presents an assay framework grounded in the Liu et al. study.
-
DNase I (RNase-free): From Clean RNA to Rigor
2026-09-18
DNA carryover is not a minor cleanup issue in RNA research; it can distort reverse-transcription assays, obscure transcript integrity, and weaken translational decisions. This thought-leadership article explains how DNase I (RNase-free) can be deployed as a strategically controlled preanalytical step across RNA extraction, in vitro transcription, chromatin studies, and long self-amplifying RNA quality assessment.
-
A-1331852: BCL-XL Inhibitor Workflow
2026-09-18
A-1331852 is a potent, selective BCL-XL inhibitor for linking target engagement with mitochondrial apoptosis in cancer research. This practical guide covers compound handling, apoptosis assay design, BCL-XL–BIM complex disruption, combination studies, and troubleshooting for reproducible preclinical workflows.
-
Berberine Hydrochloride: AMPK Assay Workflows
2026-09-17
Build reproducible Berberine hydrochloride workflows for AMPK signaling, LDL receptor regulation, lipid metabolism modulation, and cancer assays. This guide translates a cardiotoxicity study into practical assay design while separating evidence-backed findings from exploratory recommendations.
-
Short-Scale BIR Amplifies DNA Damage in Oocytes
2026-09-17
The reference study identifies short-scale break-induced replication (ssBIR) as a DNA synthesis response to double-strand breaks in fully grown mouse oocytes. Its combination of EdU labeling, damage-marker analysis, developmental-stage comparison, and replication-pathway inhibitors supports a model in which Rad51-dependent repair can amplify, rather than simply resolve, DNA damage.
-
Chloroquine Diphosphate in Ferroptosis Assays
2026-09-16
Build more informative cancer research workflows with Chloroquine Diphosphate as an autophagy, TLR7/TLR9, and cell-cycle perturbation tool. This guide shows how to pair it with orthogonal ferroptosis readouts, chemotherapy sensitization studies, and disciplined troubleshooting without mistaking autophagic flux changes for proof of cell death.
-
TAI-1: A Mechanistic Map of Hec1 Inhibition
2026-09-15
TAI-1 is a first-in-class Hec1 inhibitor that converts mitotic checkpoint disruption into a tractable cancer research strategy. This article distinguishes Hec1-driven mitotic stress from WEE1-associated transcription–replication damage and develops an assay framework for interpreting selectivity, synergy, and biomarker response.
-
Entinostat (MS-275): Practical HDAC1/3 Assays
2026-09-15
Build sharper epigenetic experiments with Entinostat (MS-275), from solvent-controlled cancer cell assays to time-resolved regeneration studies. This workflow separates HDAC target engagement, growth arrest, apoptosis induction, and tissue-level phenotypes instead of treating viability loss as a single endpoint.
-
Müller Cell PEDF Controls Retinal Neuron Survival
2026-09-14
The reference study identifies Müller cell-derived pigment epithelium-derived factor (PEDF) as a key intermediary linking angiopoietin balance to retinal neuronal survival through Tie-2–PI3K/Akt signaling. Its co-culture, knockdown, and rescue experiments provide a useful framework for studying neurovascular interactions under hypoxic stress.
-
FK866 (APO866) Workflow for NAMPT Research
2026-09-14
FK866 (APO866) enables controlled investigation of NAMPT-dependent NAD depletion, with practical applications spanning hematologic cancer research, mitochondrial injury, and pathway validation. This workflow emphasizes dose finding, orthogonal metabolic readouts, and careful interpretation of caspase-independent cell death rather than relying on viability data alone.